In recent years, in addition to its own medical material products, Medeon has also acquired a US-based innovative medical material company to enter the high-end medical material contracted research and development manufacturing service (CDMO), adopting the one-stop service of receiving orders and trial production in the US and mass production in Taiwan.

Deputy General Manager Jenny Chen said that large players are not interested in small quantities and multiple cases that require collaborative development.

Since the end of last year, Medeon has acquired three US medical materials companies and their innovative technologies, including MediBalloon, a manufacturer of high-pressure balloons and tubing; Second Source Medical, a manufacturer of semi-finished and finished products for assembly; and Medeonbio, a manufacturer of precision catheters.

Through the start-up company, Medeon will develop prototypes for its customers, and when mass production is reached, the products will be transferred to Medeon's subsidiary, Medeon Biomedical, for production, with the operation of taking orders in the US, trial production locally and mass production in Taiwan.

Chen mentioned that CDMO has served more than 40 large and small US medical material customers, and has not had any customer switching orders so far, with a retention rate of 100%.

The clinical trial of Urocross, a minimally invasive treatment material for enlarged prostate, is expected to be completed in the first half of 2024, with over 300 patients to be treated for six months and followed up for six months, with preliminary clinical data available in 2024 and 2025 at the earliest, and the overall trial completion date falling in 2027.

In addition, the US FDA has started to arrange cGMP field audits for the large diameter cardiac catheter hemostasis device, Cross-Seal, and will recognise $110 million when the marketing approval for the product is obtained and the product is launched.